- Home
- IMCC vs GLTO Comparison
IMCC vs GLTO Comparison
Compare IMCC & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCC
- GLTO
- Stock Information
- Founded
- IMCC 1980
- GLTO 2011
- Country
- IMCC Israel
- GLTO Denmark
- Employees
- IMCC N/A
- GLTO N/A
- Industry
- IMCC Medicinal Chemicals and Botanical Products
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- IMCC Health Care
- GLTO Health Care
- Exchange
- IMCC Nasdaq
- GLTO Nasdaq
- Market Cap
- IMCC 8.8M
- GLTO 7.5M
- IPO Year
- IMCC N/A
- GLTO 2020
- Fundamental
- Price
- IMCC $1.99
- GLTO $4.79
- Analyst Decision
- IMCC
- GLTO Buy
- Analyst Count
- IMCC 0
- GLTO 1
- Target Price
- IMCC N/A
- GLTO $10.00
- AVG Volume (30 Days)
- IMCC 245.1K
- GLTO 17.2K
- Earning Date
- IMCC 11-14-2024
- GLTO 11-01-2024
- Dividend Yield
- IMCC N/A
- GLTO N/A
- EPS Growth
- IMCC N/A
- GLTO N/A
- EPS
- IMCC N/A
- GLTO N/A
- Revenue
- IMCC $38,042,859.00
- GLTO N/A
- Revenue This Year
- IMCC $22.59
- GLTO N/A
- Revenue Next Year
- IMCC $20.53
- GLTO N/A
- P/E Ratio
- IMCC N/A
- GLTO N/A
- Revenue Growth
- IMCC N/A
- GLTO N/A
- 52 Week Low
- IMCC $1.13
- GLTO $4.78
- 52 Week High
- IMCC $8.10
- GLTO $23.50
- Technical
- Relative Strength Index (RSI)
- IMCC 40.31
- GLTO 26.83
- Support Level
- IMCC $2.01
- GLTO $5.50
- Resistance Level
- IMCC $2.65
- GLTO $5.36
- Average True Range (ATR)
- IMCC 0.38
- GLTO 0.38
- MACD
- IMCC -0.11
- GLTO 0.02
- Stochastic Oscillator
- IMCC 6.05
- GLTO 0.71
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.